UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
PHARMACEUTICAL COMPANIES

Agile Therapeutics

A

Agile Therapeutics

Pharmaceutical CompaniesPrinceton, United States
Visit Website

About Agile Therapeutics

Agile Therapeutics is a women's healthcare company focused on developing and commercialising innovative contraceptive products for women. Founded in 1997 and headquartered in Princeton, New Jersey, the company has built its identity around addressing unmet needs in female health, with a particular emphasis on transdermal delivery technologies.

The company's lead commercial product is Twirla, a once-weekly contraceptive patch approved by the US Food and Drug Administration in 2020. Twirla is designed as a lower-dose hormonal option, delivering ethinyl estradiol and levonorgestrel through the skin over a seven-day wear period. The product represented a meaningful addition to the prescription contraceptive market, offering women an alternative to daily oral regimens.

Agile Therapeutics trades on the Nasdaq Capital Market under the ticker symbol AGRX. The company operates primarily within the United States pharmaceutical market, working with specialty pharmaceutical distributors and healthcare providers to expand patient access to its contraceptive portfolio. Its commercial and regulatory efforts are concentrated on the women's health sector, a therapeutic area that has historically received limited innovation relative to its scale of unmet need.

The company's pipeline and commercial strategy reflect a broader commitment to women's health, with transdermal patch technology forming the foundation of its product development approach. Agile Therapeutics represents the smaller end of the specialty pharmaceutical landscape, with a focused remit rather than the diversified portfolio of larger pharmaceutical groups.

Further information is available at agiletherapeutics.com.

Similar Companies

More in Pharmaceutical Companies

A

Astellas Europe

Astellas Europe represents the regional operations of Astellas Pharma Inc., a Japanese global pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. Listed on the Tokyo Stock Exchange (ticker: 4503) and employing approximately 14,000 people worldwide, Astellas positions itself at the intersection of rigorous science and patient-centred value creation, with its European presence playing a significant role in clinical development, commercial operations, and medical affairs across the region. Therapy Areas and Commercial Portfolio The company's established commercial portfolio reflects a focused strategy across several specialist areas. In oncology and urology, enzalutamide (marketed as Xtandi) for metastatic prostate cancer stands as one of the group's flagship medicines, developed in partnership with Pfizer. Transplantation medicine remains a historical strength, with tacrolimus (Prograf) continuing to serve patients requiring immunosuppression following organ transplant. Overactive bladder is addressed through mirabegron (Betmiga), a beta-3 adrenoceptor agonist that expanded treatment options beyond established anticholinergic therapies. These products underpin the European business while the pipeline advances next-generation candidates. Research Priorities and Open Innovation Astellas concentrates its research investment on four primary scientific focuses: blindness and regeneration, genetic regulation, immuno-oncology, and targeted protein degradation. Drug discovery capabilities support candidate progression from early research through clinical trials, and external funding partnerships broaden the scope of scientific enquiry beyond internal capacity. Open innovation platforms, including the SakuLab facilities in Tsukuba and Cambridge and the TME iLab initiative, provide frameworks for collaboration with external researchers and institutions. Patient centricity is embedded structurally across the organisation, combining patient partnerships, medical intelligence, behavioural science expertise, and patient insights into a coherent programme that informs both the direction of science and standards of corporate governance. Manufacturing and supply operations complement the research enterprise, supporting the integrated model from discovery to commercial availability across European markets. Further information is available at astellas.com/eu/.

View profile
A

Alfasigma USA

Formed to bring the portfolio of its Italian parent directly to North American prescribers, Alfasigma USA is the dedicated US commercial subsidiary of Alfasigma S.p.A., the Bologna-headquartered pharmaceutical group created in 2016 through the merger of Alfa Wassermann and Sigma-Tau. The parent operates in more than 90 countries and employs over 3,000 people globally, with a broad product portfolio spanning gastroenterology, hepatology, metabolism and rare disease. US Commercial and Medical Affairs Operations Alfasigma USA manages the full commercial lifecycle for its prescription medicines in the United States, covering regulatory submissions to the FDA, medical affairs, pharmacovigilance and market access. The subsidiary works directly with physicians, gastroenterologists, specialist prescribers, pharmacists and payer organisations to support appropriate product access and patient support programmes. The gastroenterology and hepatology franchise is a core focus of the US operation, reflecting the parent group's longstanding research heritage in digestive health and liver function. Alfasigma USA operates within the frameworks established by the FDA and applicable federal healthcare regulations, functioning as an accountable commercial and regulatory presence rather than relying on third-party licensing or distribution arrangements. Further information is available at alfasigmausa.com.

View profile
A

Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company advancing an emerging class of orally available small molecule drugs known as allosteric modulators, targeting neurological disorders and other indications with significant unmet need. Headquartered in Switzerland, the company combines a proprietary technology platform with a diversified pipeline spanning both clinical and pre-clinical programmes. Allosteric modulation, the mechanism at the heart of Addex's research, works by binding to sites on a receptor that are distinct from the primary active site. This approach offers potential advantages in selectivity and tolerability compared with conventional orthosteric drug design, making it a focus of growing interest in CNS drug discovery. The company's pipeline includes Dipraglurant, an mGlu5 negative allosteric modulator being evaluated for post-stroke and traumatic brain injury recovery, alongside ADX71149, an mGlu2 positive allosteric modulator developed in partnership with external collaborators. Two further GABAB positive allosteric modulator programmes address substance use disorder and chronic cough, extending the platform's reach beyond strictly neurological indications into respiratory disease. Addex supports its development activities through strategic partnerships and collaborations, which play a central role in advancing individual pipeline assets. The company is listed on the SIX Swiss Exchange and files with the SEC, maintaining US American Depositary Share (ADS) holders alongside European shareholders. Further information is available at addextherapeutics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy